Human papilloma virus E1-specific T cell immune response is associated with the prognosis of cervical cancer patients with squamous cell carcinoma

• DOI: 10.1186/s13027-018-0206-5
• Publication Date: 2018-11-16T15:44:08Z
• Authors: Miaomiao Ma; Yaning Feng; Peiwen Fan; Xuan Yao; Yanchun Peng; Tao Dong; Ruozheng Wang
• Keywords: ELISPOT; Univariate analysis

Cervical cancer is attributable to human papilloma virus (HPV) infection in the majority cases. E1, an HPV derived-protein, plays important role initiation and development of cervical cancer. Our study aims investigate E1-specific T cell response patients with squamous carcinoma (CSCC). A total 66 CSCC FIGO stage IIB-IIIB 60 healthy controls were enrolled. Enzyme-Linked ImmunoSpot (ELISPOT) assays was used measure peripheral blood these before treatment. The treated chemotherapy and/or radiotherapy followed up clinically for three years. relationship between response, various clinical characteristics prognosis studied univariate analysis, multivariate analysis survival curve analysis. frequency 59.09%, mean intensity 24.56 SFC/106 PBMCs. higher than controls(p < 0.001; p = 0.009). responses IIB no pelvic lymph node metastasis (p 0.038; 0.044). Univariate showed that E1 specific associated progression-free (PFS) overall (OS) (PFS: 0.021; OS: 0.004). Multivariate independent prognostic factor influencing PFS OS among all factors included our HR 7.252, 95%CI 1.690–31.126, 0.008; 7.499, 1.661–33.856, curves rate significantly those who did not response. demonstrated level correlated advanced CSCC. Patients displayed more likely be poor prognosis.